Valneva SE
Specialty vaccine company developing and commercializing vaccines for infectious diseases.
VLA | PA
Overview
Corporate Details
- ISIN(s):
- AT0000A10B99 (+3 more)
- LEI:
- 969500DIVIP5VKNW4948
- Country:
- France
- Address:
- 6 RUE ALAIN BOMBARD, 44800 SAINT-HERBLAIN
- Website:
- https://valneva.com/
- Sector:
- Manufacturing
Description
Valneva SE is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet medical needs. The company has leveraged its expertise to commercialize three vaccines, including a single-shot vaccine for chikungunya. Its research and development pipeline features a broad range of vaccine candidates, including those targeting Lyme disease, Shigella, and Zika.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2022-09-16 22:30 |
Valneva and IDT Biologika Agree on Termination of their COVID-19 Collaboration
|
English | 152.9 KB | ||
| 2022-09-16 22:30 |
Valneva et IDT Biologika mettent fin à leur collaboration sur COVID-19 d’un com…
|
French | 195.4 KB | ||
| 2022-09-08 10:02 |
Rapport financier semestriel 2022
|
French | 2.1 MB | ||
| 2022-09-08 07:00 |
Valneva et VBI Vaccines Annoncent un partenariat pour la commercialisation et l…
|
French | 191.0 KB | ||
| 2022-09-08 07:00 |
Valneva and VBI Vaccines Announce European Partnership for Marketing and Distri…
|
English | 190.0 KB | ||
| 2022-09-06 07:00 |
Valneva annonce la publication dans le Lancet Infectious Diseases des résultats…
|
French | 177.7 KB | ||
| 2022-09-06 07:00 |
Valneva Announces Publication of its COVID-19 Vaccine Phase 3 Data in The Lance…
|
English | 173.5 KB | ||
| 2022-09-05 18:00 |
VALNEVA - Déclaration d’actions et de droits de vote : 31 août 2022
|
French | 18.9 KB | ||
| 2022-09-05 18:00 |
VALNEVA - Declaration of shares and voting rights: August 31, 2022
|
English | 18.9 KB | ||
| 2022-08-29 07:00 |
Valneva annonce de nouveaux résultats positifs d’immunogénicité de Phase 3 et l…
|
French | 220.6 KB | ||
| 2022-08-29 07:00 |
Valneva Reports Further Positive Phase 3 Immunogenicity and the First Heterolog…
|
English | 180.7 KB | ||
| 2022-08-23 17:45 |
Valneva confirme les recommandations de l'OMS pour son vaccin inactivé contre l…
|
French | 159.5 KB | ||
| 2022-08-23 17:45 |
Valneva Confirms WHO Recommendations for its Inactivated COVID-19 Vaccine
|
English | 151.1 KB | ||
| 2022-08-18 18:00 |
Valneva Initiates Rolling Submission of FDA Biologics License Application for i…
|
English | 162.0 KB | ||
| 2022-08-18 18:00 |
Valneva débute la soumission progressive du dossier de demande d’autorisation d…
|
French | 201.8 KB |
Automate Your Workflow. Get a real-time feed of all Valneva SE filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Valneva SE
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Valneva SE via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-03-18 | N/A | Other | Buy | 44,222 | N/A |
| 2024-01-03 | N/A | Other | Other | 34,802 | N/A |
| 2023-06-20 | N/A | Other | Sell | 192,547 | 1,406,228.50 EUR |
| 2023-06-19 | N/A | Other | Sell | 30,661 | 209,629.26 EUR |
| 2023-06-16 | N/A | Other | Sell | 85,589 | 582,493.06 EUR |
| 2023-06-15 | N/A | Other | Sell | 28,179 | 189,503.78 EUR |
| 2023-06-14 | N/A | Other | Sell | 228,951 | 1,519,914.11 EUR |
| 2023-06-13 | N/A | Other | Sell | 29,401 | 187,922.37 EUR |
| 2023-06-12 | N/A | Other | Sell | 117,854 | 733,782.57 EUR |
| 2023-05-10 | N/A | Other | Buy | 87,523 | N/A |
Peer Companies
